Malignant melanoma of the sinonasa l cavity is an uncommon disease, and theref ore a limited amount ofdata exists regarding its optimal treatm ent. The course ofthe disease is highly variable. Individual survival is also highly variable, but the overall prognosis is p oor; probably because patients gene rally present at a late stage and because the disease has a proclivity f or distant dissemination. We describe 2 recent cases of primal)' malignant melanoma ofthe sinonasal mucosa, and we review the literatu re.
Introduction
Malignant melanoma of the sinonasa l muco sa is an uncommon disease, and survival is poor. Diagnosis is often delayed becau se the onset of symptoms is insid ious. The pauc ity of rep orted cas es limits researchers' ability to perform randomiz ed , prospective trials. Th erefore, retro spective reviews and case reports are imp ortant for assessing the disease and its response to treatment.' With that in mind , we descr ibe 2 new cases of malignant melanoma of the sinonasa l muc osa that were recently treated at our institution durin g a 4-month period.
Case reports
Patient 1. A 77-year-old man presented to the emergen cy department with recurrent epistaxis fro m his right naris. Upon his referral to the otolaryngology clin ic, a fria ble lesion was noted in his right nasal vault. Th e result s of a biop sy taken at that time-the nasal mucosa was positive for HMB-45 and melan -A (figure I, A and B) and negative for S-l 00, pan-cytokeratin, synaptophysin, chromogranins, and Epstein-Barr virus (EBV) immunoperoxidase-were con sistent with malignant melanoma. Computed tomography (CT) of the sinuses revealed the presence of an expansile lesion in the right ethmoid air cell with exten sion into the right nasal cavity and orbit (figure I, C) . Positron-emission tomography (PET) demonstrated uptake in the right ethmoid sinus, right submandibular gland, right and left ju gul ar digastric lymph node s, and right adrenal gland.
The patient unde rwent endoscopic sinus surgery for debulking of the tumo r in the right ethmoid cavity, Postoper atively, how ever, he developed a rapid recurrence of the tumor, and he continued to ex perience right-sided epistaxis. The recurrent tumor was aggressi ve in nature, rapidly enlarging and extending into the orbit. The patient was treated with nasal packing and repe at surgical debulk ings. Following the third debulking, he had no further probl em s with epi staxis, even though his nasal cavity was filled with tum or. Twelve months after presentation, he died of meta static disease.
Patient 2. A 67-year-old man pre sented to the otolaryngo logy clinic with a 3-month histor y of left nasal obstruction. CT of the par anasal sinuses revealed opacification of the left nasal cavity and port ions of the left paranasal sinuses (figure 2, A). The patient underwent endoscopic sinus surgery for tissue debulking. Findings on biopsy were cons istent with malignant melanoma.
Th e exact origin of the tum or was diffi cult to ascertain. Th e biopsy sample exhibited pleomorphic and epithelioid subtype ch aracteristic s with nodular and flat spreading grow th pattern s (figure 2, B). Immunohistochemical staining was positive for HMB-45 and S-l 00 and negative for pan -cytok eratin , epithelial membrane anti gen, sy naptophy sin, chromogranins, and EBV immunoperox idase. CT of the neck and ches t and a PET sca n were all negati ve for distant disease.
Four week s postope ratively, the patient developed two nodul es on his left septum (figure 2, C) . He was taken back to the operating room for resection of the septum and wide local excision of the nasal mucosa. Final margin s were clear of disease. The patie nt completed a course of postoperat ive radiation therapy. Nine month s after presentation, he was bei ng monitored closely for rec urrence.
Discussion
Malignant melanom a of the sinonasa l mucosa acco unts for only 1.3% ofall malignant melanomas.' Most mucosal me la nomas (55 % ) occ ur in the head and neck .? The incidence of the disease is rough ly equa l among men and wo men, and most patients with the disease presen t between the age s of60 and 80 years.':" Symptoms on prese ntation can include nasal obstruction, epistaxis, swelI ing of the nose or the presence of a visib le mass at the vestib ule, pain, and nasa l discharge.Y! ':" Diplopia and proptosis have been doc umented as late findings.II Patients with mucosa l melanoma tend to present later in the disease co urse than do patients with cutaneo us mela noma, most likely beca use their symptoms are ofte n associated with ben ign con ditio ns that may be ignored ear ly on. Persistent symp toms warra nt a thorough eva luatio n to excl ude neopl astic disease.
Th e diagn osis is dependent on histologic findings. Mu cosal melano ma differs fro m cutaneo us melanoma in that the former frequentl y lacks melanin pigment.13 Also, a lack of histo logic landmarks for mucosal melanom a prec ludes accurate staging; there is no epidermis-to-der mis interface, making it difficu lt to determ ine the tumo r's dept h of inva sion . Many surgical specimens become fragmented upo n removal.
Micro scopic finding s include surface deviatio n, pagetoid spread, pigme ntation , giant-cell formatio n, and necrosis. Other findings inclu de a spindle-shaped, peritheliom atous, solid-sheet, or meningo thelial grow th pattern and a spindle-cell, epithe lioid, plasmacyto id, rhabdo id, or undiffere ntiated subtype." Immu noh istochemical stains aid in the diagnosis. S-100 protein, HMB-45 (gp I 00), tyrosine, melan-A, microphthalmia transcription fac tor, vimentin, neuron-specific eno lase, CD 117, CD99, sy napto phys in, CD5 6, and CD57 stains have all bee n iden tified in malignant melanoma.P:"
Th e unco mmon nature of sinonasal malignant melanoma makes it difficult to predict its outco me, but we do know that the prog nosis is poor. Suggested poor prog nostic factor s incl ude age greater than 60 yea rs at presen tation, present ation with ob str uctive sy mpto ms only, the location of a tumor in the nasoph aryn x, an und ifferen tiated histology, more than 10 mitotic figures per 10 high-power field, and the dev elopment of a rec urre nce .12 Addit ional poor pro gno stic factor s incl ude advanced cl inic al stage at presentat ion, tum or thickn ess grea ter than 5 mm , the presence of vascular inva sio n, and the development of distant metastases." T he prese nce of positive lymph nodes has also been indicated as a poor prognostic indicator.' Early stage at pres en tation has been sho w n to predict a more favorable outc ome .IS Ag gressiv e surge ry aimed at ac hievi ng local co ntro l is the -preferred meth od of treatmen t. Resection options include radi cal surge ry (partial or tota l maxillectomy with or witho ut or bit exentera tio n) or local resectio n (debulking or wide loc al excisio n). Total surgica l excis ion is not alway s pos sib le beca use of the location of the tum or and adjacent structure s. Ag gressive resectio n can achieve local control." Loc al contro l has been sho wn to increase sur viva l in so me studies.":"
The interv al between the treatment of the initia l tumor and its recurrence is highl y variable; the re ported ra nge of local rec urr ences is I to 12-plus yea rs.3.4.6.16.17Al tho ugh rad iat ion thera py alone has been show n to res ult in co mplete or partia l control init ia lly," :'? neither radiati on nor chem ot hera py, singly or co mbined, has been sho w n to affect overa ll survival.Y ":" In a re tros pec tive review of 69 pati ent s, Ternam et al fo und that the addi tion of po stoper ativ e radi ation therapy improved local co ntro l but wor sen ed ov erall s urv iva l.J7 Con versely, in a rev iew of 13 pa tient s, Volume 86, Number 5 Kingdom and Kap lan rep orted that po stoperative radiation therapy was associated with better overall surv iva l and bett er disea se-fre e surviva l." Chemother apy has been sho wn to pro vid e little or no benefit in the treatment of the disease.": '? Im mun otherapy is still experi men tal.
Rep orted5-ye ar survival rates fo r pati ent s with mu cosal melanoma ra nge from 10 to 47 % (tab le). Ten-year survival rates ran ge fro m 20 to 24.3 %. 2-4.6-9.11.12.15.17.20 Disease-related mor tal ity is ass ociated with local or reg ional rec urrence wit h metastasis.v' :" Th e common sites of meta sta sis are the lung, liver, bone.v" and brai n. s . 9 . 13 • to test for alle rgic se nsitivity to potent ial skin irritants (s kin-prick test)
• to assess the vita lity of the T-cell res po nse as part of an evaluation of the immune system in patient s with an infection, ca ncer . or an immune disord er, and as a scree ning too l for older patien ts, maln ouri shed patient s, and those who are scheduled to undergo organ tran splant ation?
Cell-med iated immun ity is apparen tly an impor tant element of the host defe nses aga inst cancer. A growing body of inform ati on on cell-mediated immunity to EBV is providing a stro ng basis for research o n immunoreactivity in NPC. Ce ll-med iate d immune res po nses to viruses and tum or-associat ed anti gens may have impli cati ons for enha ncing our kno wledge of the etiology, d iag nosis, and treatm ent of NPC in the near fu ture.'
Our finding that patien ts with NP C have a low degree of ce ll-media ted immun ity co nfirms a findin g by Hsu et al, who published the results of their study of 344 patien ts with NPC in I980. x Two years earlie r, Ch an et al reported that newly diag nosed NPC patient s had an imp aired T-ce ll function that was associated wit h poor surv ival."
Th e progn osis for patient s with NPC is ge nera lly poor, largely becau se it is difficult to detect in its ea rly stages. Thi s ca nce r ca n arise seconda ry to the failure of an immunosur veill ance mech an ism in which immunoresponsiveness is ex treme ly depressed. Immunologic status has been examined, and the clinica l eva luatio n of immunotherapy and lym phocyte tra nsfer has been performed by Tsukud a and Sawaki.t'Th ey found that deficiencies ofce llular immunity co uld be recognized through the various immuno log ic parameters and immunotherapy. Th ey suggested that this is indispen sable in this cancer treatm ent.
